[
    {
        "id": "iframe-item-easl-interface",
        "type": "iframe",
        "x": 1100,
        "y": 7800,
        "width": 1800,
        "height": 1200,
        "title": "EASL Web Interface",
        "iframeUrl": "https://easl-board.vercel.app/",
        "color": "#ffffff",
        "rotation": 0,
        "conversationHistory": [],
        "createdAt": "2025-10-28T12:00:00.000Z",
        "updatedAt": "2025-10-28T12:00:00.000Z"
    },
    {
        "id": "dashboard-item-1759906246155-lab-table",
        "type": "component",
        "x": 619,
        "y": 3701,
        "width": 520,
        "height": 500,
        "componentType": "LabTable",
        "color": "#ffffff",
        "description": "",
        "content": {
            "title": "Lab Findings",
            "component": "LabTable",
            "props": {
                "encounters": [
                    {
                        "encounter_no": 1,
                        "date": "2024-03-05",
                        "meta": {
                            "ui_risk_color": "amber",
                            "event_tags": [
                                "Mild ALT elevation",
                                "Possible MASLD flare"
                            ]
                        }
                    },
                    {
                        "encounter_no": 2,
                        "date": "2024-04-01",
                        "meta": {
                            "ui_risk_color": "amber",
                            "event_tags": [
                                "Prior abnormal LFTs",
                                "Chronic liver disease risk"
                            ]
                        }
                    },
                    {
                        "encounter_no": 3,
                        "date": "2024-05-06",
                        "meta": {
                            "ui_risk_color": "green",
                            "event_tags": [
                                "LFT normalization",
                                "Viral/autoimmune/metabolic workup negative"
                            ]
                        }
                    },
                    {
                        "encounter_no": 4,
                        "date": "2024-06-03",
                        "meta": {
                            "ui_risk_color": "green",
                            "event_tags": [
                                "Stable labs",
                                "Safe to initiate MTX"
                            ]
                        }
                    },
                    {
                        "encounter_no": 5,
                        "date": "2024-07-15",
                        "meta": {
                            "ui_risk_color": "red",
                            "event_tags": [
                                "ALT 185 U/L (4.6× ULN)",
                                "Severe DILI warning",
                                "MTX toxicity suspected"
                            ]
                        }
                    },
                    {
                        "encounter_no": 6,
                        "date": "2024-08-12",
                        "meta": {
                            "ui_risk_color": "red",
                            "event_tags": [
                                "ALT 490 U/L (12× ULN)",
                                "Bilirubin 110 μmol/L",
                                "Severe acute DILI",
                                "Emergency admission"
                            ]
                        }
                    },
                    {
                        "encounter_no": 7,
                        "date": "2024-08-15",
                        "meta": {
                            "ui_risk_color": "red",
                            "event_tags": [
                                "Bilirubin 190 μmol/L (peak cholestasis)",
                                "Ongoing severe DILI",
                                "Inpatient hepatology"
                            ]
                        }
                    }
                ]
            }
        },
        "createdAt": "2025-10-14T16:50:46.155Z",
        "updatedAt": "2025-11-21T08:36:42.289Z"
    },
    {
        "id": "dashboard-item-1759906246156-lab-chart",
        "type": "component",
        "x": 620,
        "y": 4304,
        "width": 520,
        "height": 500,
        "componentType": "LabChart",
        "color": "#ffffff",
        "description": "",
        "content": {
            "title": "Lab Trends",
            "component": "LabChart",
            "props": {
                "encounters": [
                    {
                        "encounter_no": 1,
                        "date": "2024-03-05",
                        "meta": {
                            "ui_risk_color": "amber",
                            "event_tags": [
                                "ALT 78 U/L",
                                "Mild hepatocellular elevation"
                            ]
                        }
                    },
                    {
                        "encounter_no": 2,
                        "date": "2024-04-01",
                        "meta": {
                            "ui_risk_color": "amber",
                            "event_tags": [
                                "Persistently abnormal LFTs",
                                "MASLD risk"
                            ]
                        }
                    },
                    {
                        "encounter_no": 3,
                        "date": "2024-05-06",
                        "meta": {
                            "ui_risk_color": "green",
                            "event_tags": [
                                "ALT normalized (35 U/L)",
                                "Workup negative"
                            ]
                        }
                    },
                    {
                        "encounter_no": 4,
                        "date": "2024-06-03",
                        "meta": {
                            "ui_risk_color": "green",
                            "event_tags": [
                                "Stable labs",
                                "MTX initiation"
                            ]
                        }
                    },
                    {
                        "encounter_no": 5,
                        "date": "2024-07-15",
                        "meta": {
                            "ui_risk_color": "red",
                            "event_tags": [
                                "ALT 185 U/L (4.6× ULN)",
                                "Severe MTX toxicity warning"
                            ]
                        }
                    },
                    {
                        "encounter_no": 6,
                        "date": "2024-08-12",
                        "meta": {
                            "ui_risk_color": "red",
                            "event_tags": [
                                "ALT 490 U/L (12× ULN)",
                                "Bilirubin 110 μmol/L",
                                "Severe DILI"
                            ]
                        }
                    },
                    {
                        "encounter_no": 7,
                        "date": "2024-08-15",
                        "meta": {
                            "ui_risk_color": "red",
                            "event_tags": [
                                "Bilirubin 190 μmol/L (peak)",
                                "Ongoing severe DILI"
                            ]
                        }
                    }
                ],
                "medicationTimeline": [
                    {
                        "name": "Metformin",
                        "start": "2019-01-01",
                        "dose": "1000mg BD"
                    },
                    {
                        "name": "Ramipril",
                        "start": "2020-01-01",
                        "dose": "5mg daily"
                    },
                    {
                        "name": "Methotrexate",
                        "start": "2024-06-03",
                        "end": "2024-08-12",
                        "dose": "7.5mg weekly initially; reduced to 5mg weekly on 2024-07-15"
                    },
                    {
                        "name": "Folic Acid",
                        "start": "2024-06-03",
                        "dose": "5mg weekly"
                    },
                    {
                        "name": "N-Acetylcysteine (IV)",
                        "start": "2024-08-12",
                        "end": "2024-08-17",
                        "dose": "3-bag protocol"
                    },
                    {
                        "name": "Ursodeoxycholic Acid",
                        "start": "2024-08-15",
                        "dose": "500mg BID"
                    }
                ]
            }
        },
        "createdAt": "2025-10-14T16:50:46.156Z",
        "updatedAt": "2025-11-21T08:36:34.517Z"
    },
    {
        "id": "dashboard-item-1759906300004-single-encounter-4",
        "type": "component",
        "x": -1300,
        "y": 800,
        "width": 500,
        "height": 600,
        "componentType": "SingleEncounterDocument",
        "color": "#ffffff",
        "description": "",
        "content": {
            "title": "Encounter #4 - Outpatient",
            "component": "SingleEncounterDocument",
            "props": {
                "encounter": {
                    "encounter_no": 4,
                    "meta": {
                        "visit_type": "Outpatient",
                        "date_time": "2024-06-03T11:30:55",
                        "provider": {
                            "name": "Dr. P. Stevens",
                            "specialty": "Unknown"
                        },
                        "ui_risk_color": "yellow"
                    },
                    "assessment": {
                        "impression": "Initiation of Methotrexate for Rheumatoid Arthritis management.",
                        "differential": []
                    },
                    "chief_complaint": "Initiation of Disease-Modifying Anti-Rheumatic Drug (DMARD) - Methotrexate (MTX) for Rheumatoid Arthritis (RA) management.",
                    "hpi": "Sarah Miller presents for the initiation of Methotrexate treatment for RA. She reports her joint pain has been stable but remains a significant source of discomfort, affecting her daily activities. A thorough review of her medical history, medication adherence, and lifestyle was conducted. The patient confirms receipt and comprehension of the Methotrexate informational leaflet, indicating understanding of the treatment regimen and potential adverse effects. The decision to commence Methotrexate was made following normalization of liver function tests (LFTs) as of May 6, 2024. The patient reiterated understanding of the importance of strict compliance with the monitoring schedule due to the severe hepatotoxicity risk associated with Methotrexate.",
                    "medications_prior": [],
                    "physical_exam": {
                        "general": "Vital Signs: BP 138/86 mmHg (sitting), HR 80 bpm, RR 15/min, Temp 36.7°C, SpO₂ 98% on room air. Anthropometrics: Weight 84 kg (BMI 31.2 kg/m²). Weight stable compared with early May.",
                        "msk": "",
                        "other_systems": ""
                    },
                    "plan": {
                        "investigations": {
                            "imaging": [],
                            "labs": [
                                "LFTs every six weeks",
                                "Full Blood Count (FBC) every six weeks"
                            ]
                        },
                        "management": {
                            "follow_up": "First LFT/FBC evaluation scheduled for July 15, 2024. Regular monitoring every six weeks for the next 6 months. Patient to contact clinic immediately if severe nausea, vomiting, or jaundice occur.",
                            "medications_started": [
                                {
                                    "dose": "7.5mg",
                                    "frequency": "once weekly",
                                    "name": "Methotrexate",
                                    "route": "orally"
                                },
                                {
                                    "dose": "5mg",
                                    "frequency": "weekly",
                                    "name": "Folic Acid",
                                    "route": "orally"
                                }
                            ]
                        }
                    },
                    "reason_for_visit": "Initiation of Methotrexate for Rheumatoid Arthritis management."
                },
                "patient": {
                    "name": "Sarah Miller",
                    "sex": "Female",
                    "age_at_first_encounter": 43
                },
                "encounterIndex": 4,
                "dataSource": "Medilogik"
            }
        },
        "createdAt": "2025-10-15T08:00:00.000Z",
        "updatedAt": "2025-10-15T08:00:00.000Z"
    },
    {
        "id": "dashboard-item-1759906300004-single-encounter-7",
        "type": "component",
        "x": 800,
        "y": 800,
        "width": 500,
        "height": 600,
        "componentType": "SingleEncounterDocument",
        "color": "#ffffff",
        "description": "",
        "content": {
            "title": "Encounter #7 - Inpatient Hepatology Ward B",
            "component": "SingleEncounterDocument",
            "props": {
                "encounter": {
                    "encounter_no": 7,
                    "meta": {
                        "visit_type": "Inpatient",
                        "date_time": "2024-08-15T10:00:48",
                        "provider": {
                            "name": "Dr. R. Sharma",
                            "specialty": "Consultant Hepatologist"
                        },
                        "ui_risk_color": "yellow"
                    },
                    "assessment": {
                        "impression": "Severe Drug-Induced Liver Injury (DILI) secondary to Methotrexate, with a RUCAM score of 9/10, indicating a high likelihood of causation. No features of Acute-on-Chronic Liver Failure (ACLF). Underlying Metabolic Associated Steatotic Hepatitis (MASH).",
                        "differential": []
                    },
                    "chief_complaint": "Severe Drug-Induced Liver Injury (DILI)",
                    "hpi": "The patient is reviewed on Day 3 of her hospital admission following severe DILI. Methotrexate was stopped immediately upon recognizing it as the causative agent. Sarah remains significantly jaundiced; however, nausea has shown slight improvement since admission. Vital neurological signs include a stable Glasgow Coma Scale (GCS) score of 15, with no evidence of hepatic encephalopathy (HE); absence of asterixis or cognitive impairment. The ALT level, though elevated at 420 U/L, is beginning to decline, suggesting a positive response to the cessation of Methotrexate. Crucially, the INR remains stable at 1.1, indicating preserved liver synthetic function. These clinical findings collectively confirm a diagnosis of severe, cholestatic DILI in a patient with underlying Metabolic Associated Steatotic Hepatitis (MASH), markedly susceptible to hepatotoxic insults.",
                    "medications_prior": [],
                    "physical_exam": {
                        "general": "Sarah exhibits pronounced jaundice, evidenced by a total bilirubin level of 190 μmol/L. Despite this, she appears alert and reports moderate comfort under current care measures. Vital Signs (ward review): BP 128/82 mmHg, HR 96 bpm, RR 16/min, Temp 37.0°C, SpO₂ 97% on room air. Anthropometrics: Weight 81 kg (BMI 30.1 kg/m²). No significant interval weight change since admission.",
                        "msk": "",
                        "other_systems": "CNS Examination: She is fully oriented, demonstrating no neurological deficits. GCS remains a reassuring 15 with negative neurological signs including asterixis, tremor, and speech abnormalities. Cardio/Pulmonary: Vital signs are stable with no indications of fluid overload, pulmonary distress, or hepatorenal syndrome. Abdominal Examination: The abdomen is soft and non-tender. The liver edge is not easily palpable due to Sarah's body habitus, yet no tenderness is detected upon examination."
                    },
                    "plan": {
                        "investigations": {
                            "imaging": [
                                "Fibroscan in three months"
                            ],
                            "labs": [
                                "Daily INR evaluations until ALT levels fall below 150 U/L",
                                "Neurological assessments every four hours"
                            ]
                        },
                        "management": {
                            "follow_up": "Arrange a Fibroscan (Liver Stiffness Measurement) in three months to assess fibrosis arising from chronic MASH and the acute DILI event. Coordinate with Rheumatology for the initiation of a non-hepatotoxic DMARD alternative, such as Hydroxychloroquine or a biologic, to manage RA without compromising liver health.",
                            "medications_started": [
                                {
                                    "dose": "500mg",
                                    "frequency": "twice daily",
                                    "name": "Ursodeoxycholic Acid (UDCA)",
                                    "route": ""
                                },
                                {
                                    "dose": "",
                                    "frequency": "",
                                    "name": "Folic Acid",
                                    "route": ""
                                }
                            ]
                        }
                    },
                    "reason_for_visit": "Review on Day 3 of hospital admission following severe DILI."
                },
                "patient": {
                    "name": "Sarah Miller",
                    "sex": "Female",
                    "age_at_first_encounter": 43
                },
                "encounterIndex": 7,
                "dataSource": "Nervecentre"
            }
        },
        "createdAt": "2025-10-14T16:55:00.004Z",
        "updatedAt": "2025-10-14T16:55:00.004Z"
    },
    {
        "id": "dashboard-item-1759906300004-single-encounter-2",
        "type": "component",
        "x": -2700,
        "y": 800,
        "width": 500,
        "height": 600,
        "componentType": "SingleEncounterDocument",
        "color": "#ffffff",
        "description": "",
        "content": {
            "title": "Encounter #2 - Outpatient",
            "component": "SingleEncounterDocument",
            "props": {
                "encounter": {
                    "encounter_no": 2,
                    "meta": {
                        "visit_type": "Outpatient",
                        "date_time": "2024-04-01T15:00:45",
                        "provider": {
                            "name": "Dr. P. Stevens",
                            "specialty": "Unknown"
                        },
                        "ui_risk_color": "yellow"
                    },
                    "assessment": {
                        "impression": "Elevated ALT of 78 U/L, concerning for hepatocellular inflammation, potentially related to Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD). Methotrexate initiation deferred pending further investigation.",
                        "differential": [
                            "Hepatocellular inflammation",
                            "Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)",
                            "Viral Hepatitis",
                            "Autoimmune Hepatitis",
                            "Hemochromatosis",
                            "Alpha-1-Antitrypsin Deficiency"
                        ]
                    },
                    "chief_complaint": "Review of abnormal liver function tests and planning for rheumatoid arthritis treatment.",
                    "hpi": "Patient reports making small changes to diet and activity since the last visit, with an approximate 0.5–1 kg weight loss. The elevated ALT of 78 U/L was reviewed. Potential Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) was discussed as a contributing factor. Patient was educated on the significance of these results and the potential risk for liver injury if starting Methotrexate without further clearance.",
                    "medications_prior": [],
                    "physical_exam": {
                        "general": "Vital Signs: BP 142/90 mmHg (sitting), HR 80 bpm, RR 16/min, Temp 36.7°C, SpO₂ 99% on room air. Anthropometrics: Weight 85.5 kg (BMI 31.8 kg/m²).",
                        "msk": "",
                        "other_systems": ""
                    },
                    "plan": {
                        "investigations": {
                            "imaging": [],
                            "labs": [
                                "HBsAg",
                                "HCV Ab",
                                "ANA",
                                "ASMA",
                                "Ferritin",
                                "TIBC",
                                "Full liver panel"
                            ]
                        },
                        "management": {
                            "follow_up": "Return for follow-up in 4 weeks to review investigation results. Continued monitoring and lifestyle modifications advised.",
                            "medications_started": []
                        }
                    },
                    "reason_for_visit": "Review of abnormal liver function tests and planning for rheumatoid arthritis treatment."
                },
                "patient": {
                    "name": "Sarah Miller",
                    "sex": "Female",
                    "age_at_first_encounter": 43
                },
                "encounterIndex": 2,
                "dataSource": "BigHand"
            }
        },
        "createdAt": "2025-10-15T08:00:00.000Z",
        "updatedAt": "2025-10-15T08:00:00.000Z"
    },
    {
        "id": "dashboard-item-1759906300004-single-encounter-6",
        "type": "component",
        "x": 100,
        "y": 800,
        "width": 500,
        "height": 600,
        "componentType": "SingleEncounterDocument",
        "color": "#ffffff",
        "description": "",
        "content": {
            "title": "Encounter #6 - Urgent Review",
            "component": "SingleEncounterDocument",
            "props": {
                "encounter": {
                    "encounter_no": 6,
                    "meta": {
                        "visit_type": "Emergency Department (ED)",
                        "date_time": "2024-08-12T14:00:00",
                        "provider": {
                            "name": "Dr. P. Stevens",
                            "specialty": "General Practitioner"
                        },
                        "ui_risk_color": "red"
                    },
                    "assessment": {
                        "impression": "Severe, Acute Drug-Induced Liver Injury (DILI) with developing cholestasis.",
                        "differential": [
                            "Mechanical obstruction (e.g., choledocholithiasis)"
                        ]
                    },
                    "chief_complaint": "Urgent review for new onset jaundice, dark urine, and constant, severe nausea leading to anorexia.",
                    "hpi": "Patient presented with new onset jaundice, dark urine, and severe nausea leading to anorexia. Initial ED vital signs: BP 132/88 mmHg (sitting), HR 102 bpm, RR 18/min, Temp 37.3°C, SpO₂ 97% on room air. Weight 81.5 kg (BMI 30.3 kg/m²). Patient reported significant weight loss of approximately 4.5 kg over the past 4–6 weeks due to nausea and anorexia. Jaundice noted upon waking, dark urine observed. Symptoms are severe and persistent. Laboratory analysis revealed significantly elevated ALT levels and bilirubin of 110 μmol/L, indicating severe cholestasis. INR was stable at 1.1.",
                    "medications_prior": [
                        {
                            "name": "Methotrexate",
                            "route": "Oral"
                        }
                    ],
                    "physical_exam": {
                        "general": "Jaundice noted. Patient appears anorectic."
                    },
                    "plan": {
                        "investigations": {
                            "imaging": [
                                "USG Abdomen Complete - STAT (Accession Number: USG-240812-001). Report indicates severe MASH/MASLD, no mechanical obstruction. Impression: Severe hepatocellular DILI superimposed on advanced chronic liver disease (MASH)."
                            ],
                            "labs": [
                                "ALT levels elevated",
                                "Bilirubin levels elevated to 110 μmol/L",
                                "INR stable at 1.1"
                            ]
                        },
                        "management": {
                            "follow_up": "Close follow-up post-hospital discharge to reassess liver function and re-evaluate RA treatment plan, considering contraindication for future Methotrexate use.",
                            "medications_started": [
                                {
                                    "name": "N-acetylcysteine (NAC)",
                                    "route": "IV Infusion (3-bag protocol, 85kg weight)"
                                }
                            ]
                        }
                    },
                    "reason_for_visit": "New onset jaundice, dark urine, severe nausea, and anorexia, concerning for acute liver injury."
                },
                "patient": {
                    "name": "Sarah Miller",
                    "sex": "Female",
                    "age_at_first_encounter": 43
                },
                "encounterIndex": 1,
                "dataSource": "ICE/VueExplore"
            }
        },
        "createdAt": "2025-10-14T16:55:00.004Z",
        "updatedAt": "2025-10-14T16:55:00.004Z"
    },
    {
        "id": "dashboard-item-1759853783245-patient-context",
        "type": "component",
        "x": -4029,
        "y": 3700,
        "width": 1600,
        "height": "auto",
        "componentType": "PatientContext",
        "color": "#ffffff",
        "description": "",
        "content": {
            "title": "Patient Context",
            "component": "PatientContext",
            "props": {
                "patientData": {
                    "patient": {
                        "name": "Sarah Miller",
                        "date_of_birth": "1981-06-03",
                        "age": 43,
                        "sex": "Female",
                        "age_at_first_encounter": 43,
                        "identifiers": {
                            "mrn": "SM43850603"
                        }
                    },
                    "riskLevel": "high",
                    "primaryDiagnosis": "Severe Drug-Induced Liver Injury (Methotrexate-related)",
                    "problem_list": [
                        {
                            "name": "Type 2 Diabetes Mellitus",
                            "status": "active"
                        },
                        {
                            "name": "Essential Hypertension",
                            "status": "active"
                        },
                        {
                            "name": "Rheumatoid Arthritis",
                            "status": "active"
                        },
                        {
                            "name": "Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD/MASH)",
                            "status": "active"
                        },
                        {
                            "name": "Severe Methotrexate-induced Drug-Induced Liver Injury (DILI)",
                            "status": "active"
                        },
                        {
                            "name": "Acute jaundice episode (2024-08)",
                            "status": "resolved/improving"
                        }
                    ],
                    "medication_timeline": [
                        {
                            "name": "Metformin",
                            "dose": "1000 mg",
                            "route": "PO",
                            "frequency": "BD",
                            "start": "2019-01-01"
                        },
                        {
                            "name": "Ramipril",
                            "dose": "5 mg",
                            "route": "PO",
                            "frequency": "daily",
                            "start": "2020-01-01"
                        },
                        {
                            "name": "Ibuprofen",
                            "dose": "variable",
                            "route": "PO",
                            "frequency": "PRN",
                            "start": "2022-01-01"
                        },
                        {
                            "name": "Simethicone",
                            "dose": "standard",
                            "route": "PO",
                            "frequency": "PRN",
                            "start": "2024-03-05"
                        },
                        {
                            "name": "Methotrexate",
                            "dose": "7.5 mg",
                            "route": "PO",
                            "frequency": "weekly",
                            "start": "2024-06-03",
                            "end": "2024-08-12"
                        },
                        {
                            "name": "Folic Acid",
                            "dose": "5 mg",
                            "route": "PO",
                            "frequency": "weekly",
                            "start": "2024-06-03"
                        },
                        {
                            "name": "Methotrexate (dose reduced)",
                            "dose": "5 mg",
                            "route": "PO",
                            "frequency": "weekly",
                            "start": "2024-07-15",
                            "end": "2024-08-12"
                        },
                        {
                            "name": "N-Acetylcysteine (NAC IV)",
                            "dose": "3-bag protocol",
                            "route": "IV",
                            "frequency": "one-time protocol",
                            "start": "2024-08-12",
                            "end": "2024-08-17"
                        },
                        {
                            "name": "Ursodeoxycholic Acid (UDCA)",
                            "dose": "500 mg",
                            "route": "PO",
                            "frequency": "BID",
                            "start": "2024-08-15"
                        }
                    ],
                    "allergies": [
                        "Methotrexate (severe DILI – permanent contraindication)"
                    ]
                }
            }
        },
        "createdAt": "2025-10-14T16:16:23.245Z",
        "updatedAt": "2025-11-21T08:36:27.123Z"
    },
    {
        "id": "dashboard-item-1759906219477-adverse-event-analytics",
        "type": "component",
        "x": -4031,
        "y": 4444,
        "width": 1600,
        "height": "auto",
        "componentType": "AdverseEventAnalytics",
        "color": "#ffffff",
        "description": "",
        "content": {
            "title": "Adverse Event Analytics",
            "component": "AdverseEventAnalytics",
            "props": {
                "patientData": {
                    "adverseEvents": [
                        {
                            "event": "Drug-Induced Liver Injury (DILI)",
                            "severity": "Severe",
                            "description": "Severe hepatocellular DILI caused by Methotrexate, presenting with ALT 490 U/L (12× ULN), AST 350 U/L, and progressive jaundice."
                        },
                        {
                            "event": "Cholestatic Jaundice",
                            "severity": "Severe",
                            "description": "Bilirubin elevation from 110 to 190 μmol/L with marked jaundice; consistent with cholestatic component of acute DILI."
                        },
                        {
                            "event": "Methotrexate Toxicity",
                            "severity": "Severe",
                            "description": "Progressive hepatotoxicity after MTX initiation; ALT 185 U/L within 6 weeks; continued exposure led to severe acute DILI requiring hospitalization."
                        },
                        {
                            "event": "Acute-on-Chronic Liver Injury",
                            "severity": "Moderate–Severe",
                            "description": "Acute hepatocellular necrosis superimposed on underlying MASLD/MASH, demonstrated by coarse echogenic liver on ultrasound."
                        }
                    ],
                    "rucam_ctcae_analysis": {
                        "rucam": {
                            "title": "RUCAM Scoring (Hepatocellular Pattern)",
                            "columns": [
                                "#",
                                "Parameter",
                                "Key findings from this case",
                                "Score",
                                "Explanation"
                            ],
                            "rows": [
                                [
                                    "1",
                                    "Time to onset (from drug start to injury)",
                                    "MTX started 2024-06-03 → ALT rise noted by 2024-07-15 (~6 weeks)",
                                    "+2",
                                    "Typical 5–90 day window for idiosyncratic hepatocellular DILI."
                                ],
                                [
                                    "2",
                                    "Course after stopping the drug",
                                    "ALT decreased from 490 → 420 U/L by 2024-08-15 post-MTX cessation",
                                    "+3",
                                    "Fall ≥50% within 8 days supports drug causality."
                                ],
                                [
                                    "3",
                                    "Risk factors",
                                    "Female (+0), Age 43 (+0), underlying MASLD",
                                    "0",
                                    "Neither age nor sex adds RUCAM points; MASLD is a cofactor but not scored."
                                ],
                                [
                                    "4",
                                    "Concomitant drugs",
                                    "Metformin, Ramipril, Ibuprofen (non-hepatotoxic at recorded doses)",
                                    "0",
                                    "No confounding hepatotoxic co-medication recorded."
                                ],
                                [
                                    "5",
                                    "Exclusion of non-drug causes",
                                    "Negative viral serology, negative ANA/ASMA, no biliary obstruction on ultrasound",
                                    "+2",
                                    "Competing etiologies reasonably excluded."
                                ],
                                [
                                    "6",
                                    "Previous information on hepatotoxicity",
                                    "Methotrexate well-recognized hepatotoxin with documented DILI cases",
                                    "+2",
                                    "Established hepatotoxic risk."
                                ],
                                [
                                    "7",
                                    "Response to re-exposure",
                                    "Not applicable (no re-challenge)",
                                    "0",
                                    "---"
                                ]
                            ],
                            "total_score": 9,
                            "causality_category": "Highly Probable"
                        },
                        "ctcae": {
                            "title": "CTCAE Hepatic Toxicity Scoring",
                            "columns": [
                                "Criterion",
                                "Observed / Inferred",
                                "CTCAE Grade",
                                "Explanation"
                            ],
                            "rows": [
                                [
                                    "ALT/AST",
                                    "ALT 490 U/L (≈12× ULN), AST 350 U/L",
                                    "Grade 3",
                                    "ALT 5–20× ULN = Grade 3 severity."
                                ],
                                [
                                    "Total Bilirubin",
                                    "Bilirubin peaked at 190 μmol/L (≈11 mg/dL)",
                                    "Grade 3",
                                    ">3× ULN and clinical jaundice."
                                ],
                                [
                                    "INR / Coagulopathy",
                                    "INR remained 1.05–1.1 (normal)",
                                    "Grade 1",
                                    "No synthetic dysfunction; cannot qualify as Grade 4."
                                ],
                                [
                                    "Clinical Presentation",
                                    "Severe nausea, anorexia, jaundice; no hepatic encephalopathy",
                                    "Grade 2–3",
                                    "Significant symptoms without CNS involvement."
                                ]
                            ],
                            "overall_grade": "CTCAE Grade 3 — Severe but not life-threatening (no ALF or encephalopathy)"
                        },
                        "reasoning": "The patient developed acute severe hepatocellular DILI approximately 6 weeks after initiating Methotrexate. The trajectory shows progressive rise in ALT from 35 to 185 to 490 U/L, accompanied by marked jaundice and cholestasis. Viral, autoimmune, and biliary causes were excluded. INR remained stable and GCS remained 15 throughout hospitalization, confirming absence of acute liver failure. Ultrasound demonstrated severe MASLD, indicating chronic vulnerability. RUCAM score is 9 (highly probable). CTCAE grading corresponds to Grade 3 hepatic injury due to elevated bilirubin and transaminases without synthetic failure. Management appropriately included immediate MTX cessation, IV NAC protocol, hepatology admission, and initiation of UDCA."
                    }
                }
            }
        },
        "createdAt": "2025-10-14T16:50:19.477Z",
        "updatedAt": "2025-11-21T08:36:24.123Z"
    },
    {
        "id": "dashboard-item-1759906300004-single-encounter-3",
        "type": "component",
        "x": -2000,
        "y": 800,
        "width": 500,
        "height": 600,
        "componentType": "SingleEncounterDocument",
        "color": "#ffffff",
        "description": "",
        "content": {
            "title": "Encounter #3 - Outpatient Follow-up",
            "component": "SingleEncounterDocument",
            "props": {
                "encounter": {
                    "encounter_no": 3,
                    "meta": {
                        "visit_type": "Outpatient",
                        "date_time": "2024-05-06T09:00:10",
                        "provider": {
                            "name": "Dr. P. Stevens",
                            "specialty": "Unknown"
                        },
                        "ui_risk_color": "yellow"
                    },
                    "assessment": {
                        "impression": "Follow-up regarding normalization of liver function tests and initiation of Methotrexate for rheumatoid arthritis management. Normalization of LFTs with ALT at 35 U/L. Negative workup for chronic liver conditions. Likely transient elevation possibly related to MASLD. Cleared for Methotrexate initiation.",
                        "differential": [
                            "Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)",
                            "Acute self-limiting liver episode"
                        ]
                    },
                    "chief_complaint": "Follow-up regarding normalization of liver function tests (LFTs) and potential initiation of Methotrexate for rheumatoid arthritis management.",
                    "hpi": "Since the previous review, Sarah reports increased adherence to dietary advice and gentle walking most days, noting a ~1.5 kg weight loss since March. Comprehensive hepatitis workup (viral, autoimmune, metabolic) returned negative. ALT has decreased to 35 U/L, suggesting transient elevation. Patient is considered low-risk for MTX initiation.",
                    "medications_prior": [],
                    "physical_exam": {
                        "general": "Vital Signs: BP 140/88 mmHg (sitting), HR 78 bpm, RR 15/min, Temp 36.6°C, SpO₂ 99% on room air.",
                        "msk": "",
                        "other_systems": "Anthropometrics: Weight 84 kg (BMI 31.2 kg/m²)."
                    },
                    "plan": {
                        "investigations": {
                            "imaging": [],
                            "labs": [
                                "LFTs every 6 weeks",
                                "FBC every 6 weeks"
                            ]
                        },
                        "management": {
                            "follow_up": "Follow-up appointment set for early August to review treatment response, adherence to monitoring, and adjust plan. Instructed to begin Methotrexate on 2024-06-03. Emphasized adherence to strict 6-weekly monitoring schedule.",
                            "medications_started": [
                                {
                                    "dose": "7.5mg",
                                    "frequency": "weekly",
                                    "name": "Methotrexate",
                                    "route": "Unknown"
                                },
                                {
                                    "dose": "5mg",
                                    "frequency": "weekly",
                                    "name": "Folic acid",
                                    "route": "Unknown"
                                }
                            ]
                        }
                    },
                    "reason_for_visit": "Follow-up for liver function tests and rheumatoid arthritis management."
                },
                "patient": {
                    "name": "Sarah Miller",
                    "sex": "Female",
                    "age_at_first_encounter": 43
                },
                "encounterIndex": 3,
                "dataSource": "Electronic Health Record"
            }
        },
        "createdAt": "2025-10-15T08:00:00.000Z",
        "updatedAt": "2025-10-15T08:00:00.000Z"
    }
]